Moderna shares are trading higher after the company announced the publication of its Phase 3 study results evaluating mRNA-1010 in the New England Journal of Medicine.

Benzinga Newsdesk www.benzinga.com Positive 94.8%

Neg 0% Neu 0% Pos 94.8%

Comments

No comments yet. Be the first!